Executive Leadership

Joshua M. Hare, M.D. Suzanne Liv Page, JD Anthony Oliva, Ph.D.

Co-Founder and Chief Science Officer

Chief Operating Officer

Senior Scientist

Dr. Joshua Hare co-founded Longeveron in 2014 utilizing intellectual property and technology exclusively licensed from the University of Miami, where he is also the founding Director of the university’s Interdisciplinary Stem Cell Institute (ISCI). Suzanne Page is the Chief Operating Officer at Longeveron, a position she has held since the company’s inception in 2014. Over the past 20 years, Page has held senior legal and financial positions in corporate and clinical research settings. Anthony Oliva, Ph.D. joined Longeveron in 2015 as the company’s senior scientist. Earning his undergraduate degree in Biological Sciences from the University of Chicago and his Ph.D. in Neuroscience from Baylor College of Medicine, Oliva brings with him extensive experience in the fields of health science and education.
Lisa McClain-Moss Geoff Green Paul Lehr Arin Maercks

Senior Director, Production

SVP Clinical Operations

International Executive Director

Chief Commercial Officer 

Lisa McClain-Moss joined Longeveron in 2017 to lead the Company’s cell manufacturing and product development.  She has held previous leadership positions at Cognate BioServices and St. Jude’s Children Research Hospital. Geoff Green is an SVP at Longeveron and heads clinical operations including medical writing and international efforts. Paul Lehr leads Longeverons’s international efforts and programs. He earned his BA from Brown University, and his JD from University of Florida College of Law. Over the past 20 years, Lehr has held senior legal and executive positions in corporate as well as educational and not-for-profit settings. Arin Maercks joined Longeveron as the Chief Commercial Officer in 2018.  He earned an MBA from Kellogg School of Management, Northwestern University. He brings to the company a wide breadth of experience in the healthcare sector as a founding executive, operating executive, advisor and investor and will lead the company’s efforts to expand the various business units and robust portfolio of therapies offered as well as guide the future growth of partnerships and optimize commercial operations.

Scientific Advisory Board

Dr. Hidenori Arai
Jeremy D. Walston, M.D Laura L. Dugan, M.D. Elena Volpi, M.D., Ph.D. Hidenori Arai , M.D., Ph.D.
Dr. Jeremy D. Walston, M.D. is a professor of medicine at the Johns Hopkins University School of Medicine. Dr. Laura Dugan is a professor of Alzheimer’s at Vanderbilt University and the geriatric medicine head, Division of Geriatric Medicine at the Department of Medicine, Brain Institute & Neuroscience Program Dr. Elena Volpi is the distinguished chair in Geriatric Medicine at the University of Texas Medical Branch. Dr. Arai is the Deputy Director of the National Center for Geriatrics and Gerontology (NCGG) of Japan, Director of the Center for Gerontology and Social Science (CGSS) at the NCGG.